BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

Inclusion Criteria: * Admission to the ICU with severe pneumonia (IDSA/ATS 2016/2019): presence of signs, symptoms and confirmatory chest imaging consistent with pneumonia (e.g. fever, cough and pulmonary infiltrate by chest radiograph) * Age ≥18 years * Positive respiratory culture (with or without an initial positive rapid identification test and/or Gram stain) for Gram-negative bacteria including, but not limited to, P. aeruginosa, K. pneumoniae, E. coli, S. marcescens, H. influenzae, Enterobacter spp., M. catarrhalis, A. baumannii, Achromobacter spp., P. mirabilis, and/or B. cepacia * Received within the last 72 hours or will receive meropenem, cefepime, or piperacillin/tazobactam therapy Exclusion Criteria: * Pregnancy * Prisoners * Allergy to the beta-lactams to be administered in this study * On renal replacement therapy at the time of randomization * Baseline culture resistant to the beta-lactams in the study * COVID patients enrolled in other trials